Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated hodgkin tumors in SCID mice

Blood

Volumn 95, Issue 12, 2000, Pages 3909-3914

  Barth, Stefan ^a   Huhn, Michael ^a   Matthey, Bärbel ^a   Tawadros, Samir ^a   Schnell, Roland ^a   Schinköthe, Timo ^a   Diehl, Volker ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMBINED IMMUNODEFICIENCY; CYTOTOXICITY; DRUG EFFECT; HODGKIN DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

EID: 0034659745     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3909.012k04_3909_3914     Document Type: Article

References (42)

1. Gribben JG, Freedman AS, Neuberg D, at al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325: 1525.
2. Kanzler H, Hansmann mL, Kapp U, et al. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Slernberg cells of a Hodgkin's lymphoma patient. Blood. 1996;87: 3429.
3. Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Stemberg cells. Blood. 1996;87:3418.
4. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982; 299:65.
5. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68:421.
6. Gruss HJ, Dower SK. TheTNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther. 1995;1:75.
7. Wiley S, Goodwin R, Smith C. Reverse signaling via CD30 ligand. J Immunol. 1996;157:3635.
8. Sahin U, Hartmann F, Senter P, et al. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 1990;50:6944.
9. Terenzi A, Bolognesi A, Pasqualucci L, et al. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol. 1996;92:872.
10. Engert A, Burrows F, Jung W, et al. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 1990;50:84.
11. Klimka A, Barth S, Matthey B, et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer. 1999;80:1214.
12. Schnell R, Linnartz C, Katouzi AA, et al. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen, Int J Cancer. 1995;63:238.
13. Pasqualucci L, Wasik M, Teicher B, et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/ saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995;85:2139.
14. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 2000;14:129.
15. Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 1997;89:403.
16. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A. 1999;96:3957.
17. Horn-Lohrens O, Tiemann M, Lange H, et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 1995;60:539.
18. FitzGerald D, Pastan I, Robertus J. Clinical applications of immunotoxins. Intro Curr Top Microbiol Immunol. 1998;234:1.
19. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. 1992;205:263.
20. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A. Compatible solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol. 2000;66:1572
21. McCafferty J, Fitzgerald KJ, Earnshaw J, et al. Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl Biochem Biotechnol. 1994;47:157.
22. Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes, Immunol Rev. 1992;130:41.
23. Matthey B, Engert A, Klimka A, Diehl V, Barth S. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene. 1999;229:145.
24. Weis W, Harwerth I, Mueller M, Groner B, Hynes N. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992;52: 6310.
25. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press: 1989.
26. Kapp U, Wolf J, von Kalle C, et al. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol. 1992;3 (suppl 4):21.
27. Barth S, Huhn M, Matthey B, et al. The recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice, Int J Cancer. In press.
28. Bargou RC, Mapara MY, Zugck C, et al. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immuno-deficient mice. J Exp Med. 1993;177:1257.
29. Dower W. Electroporation of bacteria: a general approach to genetic transformation. Genet Eng. 1990;12:275.
30. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression ol cloned genes. J Mol Biol. 1986;189: 113.
31. Barth S, Huhn M, Wels W, Diehl V, Engert A. Construction and in vitro evaluation of RFTS(ScFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med. 1998;1: 249.
32. Winkler U, Gottstein C, Schon G, et al. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood. 1994;83:466.
33. Merz H, Malisius R, Mannweiler S, et al. Immuno-Max: a maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab Invest. 1995;73:149.
34. Klimka A, Barth S, Drillich S, et al. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interlejkin-9 (rhlL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines Mol Ther. 1996;2: 139.
35. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848.
36. Froese P, Lemke H, Gerdes J, et al. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol. 1987;139:2081.
37. Maggi E, Annunziato F, Manetti R, et al. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals. Immunity. 1995;3:251.
38. Barth S, Schnell R, Diehl V, Engert A. Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann Oncol. 1996;7(suppl 4): 135.
39. Winkler U, Barth S, Schnell R, Diehl V, Engert A. The emerging role of immunotoxins in leukemia and lymphoma. Ann Oncol. 1997;8(suppl 1):139.
40. Bera TK, Pastan I. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bioconjug Chem. 1998;9:736.
41. Reiter Y, Pai L, Brinkmann U, Wang Q, Pastan I. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 1994; 54:2714.
42. Kreitman R, Wang Q, FitzGerald D, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999;81:148.